Impact of Celecoxib restrictions in medicare beneficiaries with arthritis

Area of Science:

• Rheumatology
• Health Economics
• Pharmacoeconomics

Background:

• Osteoarthritis (OA) and rheumatoid arthritis (RA) are common conditions requiring pain management.
• Celecoxib, a selective COX-2 inhibitor, is used for arthritis pain, but formulary restrictions may alter prescribing patterns.
• Understanding the impact of these restrictions on patient outcomes and costs is crucial for healthcare management.

Purpose of the Study:

• To compare the incidence of serious gastrointestinal (GI) complications and associated medical costs in Medicare beneficiaries with OA or RA.
• To evaluate outcomes in plans with celecoxib formulary restrictions versus those without such restrictions.

Main Methods:

• Retrospective cohort analysis of Medicare members.
• Identification of members diagnosed with OA or RA.
• 1-year follow-up period to assess GI complications and costs.

Main Results:

• The group with celecoxib restrictions showed higher nonselective NSAID use (51% vs 40%) and double the celecoxib use in the unrestricted group (16% vs 8%).
• A slightly higher incidence of serious GI complications was observed in the restricted group (5.4% vs 4.6%).
• Serious GI complication-related costs were over 15 times higher in the restricted group ($1559 vs $101); overall arthritis costs were also higher ($5733 vs $3170).

Conclusions:

• Celecoxib formulary restrictions effectively reduced celecoxib utilization.
• Despite limitations in comparing different health plans, the restricted group experienced a higher incidence of serious GI complications and increased associated medical costs.
• These findings suggest that formulary restrictions may lead to unintended negative consequences on patient safety and healthcare expenditure for arthritis management.